Stretching increased skin movement, reduced skin thickness and improved mobility in a mouse model of systemic sclerosis (SSc), researchers reported. The study suggests that stretching is an under-used non-pharmacological way to treat SSc and deserves further investigation. The research, “Stretching reduces skin thickness and improves subcutaneous tissue mobility…
News
Blood vessel-dilating treatments increase blood flow equally well in digital ulcers on fingertips and in extensor surface ulcers, which occur on the opposite side of joints. This shows that a lack of blood supply — and therefore oxygen to the tissue — cause both types of ulcers in scleroderma patients.
Physician adherence to guidelines for screening for pulmonary arterial hypertension (PAH) in patients with systemic sclerosis (SSc) was found to be poor in Australia, according to a multi-center research study that evaluated the percentage of doctors who adhere to recommended SSc guidelines. The study, “Epidemiology and disease…
Corbus Pharmaceuticals will present results showing that Resunab (JBT-101), the company’s cannabis-derived treatment for systemic sclerosis (SSc), can trigger specific molecular pathways which resolve inflammation and halt fibrosis. The data will be presented by Michael L. Whitfield, PhD, a molecular biology professor at Dartmouth and scientific founder of Celdara Medical,…
A new study from France found that treatment with intravenous immunoglobulins (IVIG), known to have anti-fibrotic activity, is effective in improving muscle, joint and digestive tract function in patients with systemic sclerosis (SSc). The study, “Intravenous immunoglobulins in systemic sclerosis: data from a French nationwide cohort of 46 patients…
Patients with pulmonary arterial hypertension (PAH) linked to scleroderma have worse outcomes than those with idiopathic PAH, with survival times of less than half of iPAH patients. The difference is likely tied to numerous factors, but older age and a poor transfer of gas (abnormal oxygen-carbon monoxide transfer) in the…
People with systemic sclerosis (SSc) frequently experience foot problems, but foot assessment and healthcare for SSc patients are still inadequate, according to new research. The study, “Biomechanical Podiatric Evaluation In An Italian Cohort Of Patients With Systemic Sclerosis: A Pilot Study,” was published in the European Journal of…
Patients with severe forms of systemic sclerosis (SSc) may frequently develop fingernail abnormalities, with such changes affecting four out of five SSc patients in a small study in France. The study, “Nail Involvement in Systemic Sclerosis,” appeared in the Journal of the American Academy of Dermatology (JAAD). “Whereas skin abnormalities have been…
A large study following patients in the early stages of diffuse cutaneous scleroderma showed that immunosuppressants offered only a negligible benefit for those who took them, compared to those who didn’t. Since immunosuppressants produced numerically larger reductions in skin symptoms, the findings may support patients using such drugs from the onset of their…
Treating endothelial cells obtained from scleroderma patients with an enzyme called khloto effectively improves their function, according to a study published in the journal Arthritis Research and Therapy.
Recent Posts
- CD13 levels elevated in scleroderma, but biomarker value unclear
- New lab findings support development of stem cell treatments for SSc-ILD
- Type of immune cell may be key driver of scleroderma scarring: Study
- Abnormal fatty acid metabolism may play role in scleroderma: Analysis
- Cosmetic laser therapy could be repurposed for localized scleroderma
- Antibody levels may help reflect quality of life in people with scleroderma
- Certain antibodies tied to poorer outcomes in systemic sclerosis
- Dexamethasone reduces inflammation, scarring in SSc mouse model: Study
- Survival improves for SSc-PAH patients on combination therapy
- Combination drug therapy boosts lung, skin health in SSc patients